Pfizer Halts China Vaccine Sales Due To License Expiry
This article was originally published in PharmAsia News
Executive Summary
The largest foreign drug maker in the country has had to stop marketing its best-selling vaccine Prevenar, dealing a blow to a plan to bolster its vaccine portfolio.